Cel Lung transplantation is the only therapeutic option for selected patients suffering from end-stage lung diseases. 80% of all donated lungs are not used for transplantation. The main reason is uncertainty of the function and quality of the lung. Ex vivo lung perfusion (EVLP) is a technique used to assess quality of lungs prior to transplantation. In collaboration with leading clinical scientists, XVIVO has developed solutions and systems for EVLP. EVLP has recently become internationally clinically accepted. More than 300 patients have received transplanted lungs that would otherwise not have been used. Centers establishing a clinical program for EVLP increase the number of lung transplantations significantly. Clinical outcomes are at least equivalent to outcomes for patients receiving standard lungs. However, in order to disseminate the EVLP technique to a broader range of hospitals, it is necessary to offer objective metrics assessing lung function in addition to the subjective assessment methods used today. Exploitation of EVLP has an impact for XVIVO. Each EVLP generates an income of about €15 000. Today about 5000 lung transplantations are performed each year. If we can reach 25% increase, it would contribute to a revenue increase of at least 18 MEUR. It also means that 1250 critically ill patients on the waiting lists will receive new lungs. The true potential is to increase the utilization rate of donated lungs to 40-60%. The project aims to carefully select optimal biomarkers in phase 1 and confirm validity and clinical relevance in phase 2 through a clinical study. By introducing new biomarkers, XVIVO will be able to commercialize a device that will broaden the company´s product portfolio and fulfill the customer need for validated tools making clinicians more comfortable to use donated organs that are being discarded today. The project will be performed in collaboration with identified biomarker companies and thus also catalyze their access to market. Dziedzina nauki social sciencessociologydemographymortalitymedical and health sciencesclinical medicinetransplantation Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Zaproszenie do składania wniosków H2020-SMEInst-2014-2015 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2014 System finansowania SME-1 - SME instrument phase 1 Koordynator XVIVO PERFUSION AKTIEBOLAG Wkład UE netto € 50 000,00 Adres Mässans Gata 10 400 14 GOTEBORG Szwecja Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Södra Sverige Västsverige Västra Götalands län Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00
